Tag Archives: biotechnology law

Myriad vs. Mayo – Detection vs. Processing at the Fed. Cir.

Rapid Litigation Mgmt v. CellzDirect: Splitting Detection of a Natural Phenomenon from its Application to Yield a Product. Courtenay G. Brinkerhoff at pharmapatentsblog.com summarized the oral arguments at the Fed. Cir. (App. No. 15-1570) conducted on April 5, 2016 in … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | 1 Comment

Genetic Technologies Affirms Ariosa/Myriad With An Introduction By The Sequenom Petition for Cert.

On April 1st, Lilly filed an amicus brief in favor of Sequenom’s petition for cert. seeking to reverse Ariosa, that caused a lot of buzz in the IP community. (A copy is available at the end of this post.) To … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | 1 Comment

Superman Breyer v. Batman Lourie Battle in the Sequenom Petition for Cert.

Since this is an amplification of my last post on the Sequenom petition for cert. in Sequenom v. Ariosa, please go back at read my first post on the petition. I have been arguing for some years that the patent … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

Sequenom Files Petition for Cert. After Invalidation of Cff Patent

Sequenom, the loser in “Ariosa,” has filed a petition seeking Supreme Court review of the Fed. Cir.’s invalidation of the claims of US Pat. No. 6,258,540 as an attempt to claim a natural product, cffDNA. While there is no dispute … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment